Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
Dis Markers. 2010;29(2):81-7. doi: 10.3233/DMA-2010-0729.
Although polymorphisms in glutathione S-transferase (GST) have been associated with the risk of bladder cancer (BC), few reports provide information about the development of BC. The aim of the present study was to investigate the effect of homozygous glutathione S-transferase-μ (GSTM1) and glutathione S-transferase-ϕ (GSTT1) deletions as prognostic markers in non-muscle-invasive bladder cancer (NMIBC). A total of 241 patients with primary NMIBC were enrolled in this study. GSTM1 and GSTT1 polymorphisms were analyzed by multiplex polymerase chain reaction (PCR) using blood genomic DNA. The results were compared with clinicopathological parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox regression model. A statistically significant association between genotype and histopathological parameter was not observed. The patients with the GSTT1-positive genotype had significantly reduced recurrence- and progression-free survival than those with the GSTT1-null genotype (log-rank test, p< 0.05, respectively). Recurrence- and progression-free survival were not related to the GSTM1 genotypes. In multivariate regression analysis, the GSTT1-positive genotype was the independent predictor for recurrence [hazard ratio (HR), 1.631; p=0.043] and progression (HR, 3.418; p=0.006). These results suggested that the GSTT1 genotype could be a useful prognostic marker for recurrence and progression in NMIBC.
虽然谷胱甘肽 S-转移酶（GST）的多态性与膀胱癌（BC）的风险相关，但很少有报道提供有关 BC 发展的信息。本研究旨在探讨纯合谷胱甘肽 S-转移酶-μ（GSTM1）和谷胱甘肽 S-转移酶-ϕ（GSTT1）缺失作为非肌肉浸润性膀胱癌（NMIBC）的预后标志物的效果。本研究共纳入 241 例原发性 NMIBC 患者。采用多重聚合酶链反应（PCR）法检测血液基因组 DNA 中的 GSTM1 和 GSTT1 多态性。将结果与临床病理参数进行比较。采用 Kaplan-Meier 和多变量 Cox 回归模型评估 GSTs 的预后意义。基因型与组织病理学参数之间未观察到统计学显著关联。与 GSTT1 缺失基因型相比，GSTT1 阳性基因型的患者复发和无进展生存率显著降低（对数秩检验，分别为 p<0.05）。复发和无进展生存率与 GSTM1 基因型无关。多变量回归分析显示，GSTT1 阳性基因型是复发的独立预测因子[风险比（HR），1.631；p=0.043]和进展（HR，3.418；p=0.006）。这些结果表明，GSTT1 基因型可能是 NMIBC 复发和进展的有用预后标志物。
